BioCryst Pharmaceuticals | BCRX - Selling And Administration Expenses


BioCryst Pharmaceuticals reported $63.98M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Chugai Pharma JPY 29.04B 143M Jun/2026
Daiichi Sankyo JPY 249.96B 21.73B Jun/2026
DBV Technologies USD 13.4M 8.14M Mar/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
Incyte USD 351.73M 23.64M Jun/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Novavax USD 25.53M 1.34M Dec/2025
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026